HC Wainwright reissued their buy rating on shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) in a report published on Friday. The firm currently has a $7.00 target price on the biotechnology company’s stock.
Several other analysts also recently issued reports on the company. Zacks Investment Research upgraded Caladrius Biosciences from a sell rating to a hold rating in a report on Wednesday, July 19th. ValuEngine upgraded Caladrius Biosciences from a strong sell rating to a sell rating in a report on Friday, September 1st.
Shares of Caladrius Biosciences (NASDAQ:CLBS) traded up $0.04 during midday trading on Friday, reaching $3.05. The company had a trading volume of 17,500 shares, compared to its average volume of 58,851. Caladrius Biosciences has a 52-week low of $2.63 and a 52-week high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 141.14% and a negative net margin of 84.10%. equities analysts anticipate that Caladrius Biosciences will post -2.73 earnings per share for the current year.
WARNING: “Caladrius Biosciences, Inc. (CLBS) Given Buy Rating at HC Wainwright” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://transcriptdaily.com/2017/11/14/caladrius-biosciences-inc-clbs-given-buy-rating-at-hc-wainwright.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Caladrius Biosciences by 34.3% during the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after acquiring an additional 24,900 shares in the last quarter. KCG Holdings Inc. grew its stake in shares of Caladrius Biosciences by 74.6% during the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 15,501 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Caladrius Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after acquiring an additional 4,163 shares in the last quarter. Hedge funds and other institutional investors own 6.36% of the company’s stock.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.